Comparative Pharmacology
Head-to-head clinical analysis: PREMPRO PREMPHASE versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREMPRO PREMPHASE versus STILPHOSTROL.
PREMPRO/PREMPHASE vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prempro/Premphase contains conjugated estrogens (CE) and medroxyprogesterone acetate (MPA). Estrogens bind to estrogen receptors (ERα/ERβ), activating genomic and non-genomic signaling, promoting proliferation of estrogen-responsive tissues, and modulating lipid metabolism. MPA is a progestin that binds to progesterone receptors, antagonizing estrogen-induced endometrial hyperplasia and blunting estrogen effects on breast tissue. The combination suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary axis.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
Conjugated estrogens 0.625 mg/medroxyprogesterone acetate 2.5 mg (Prempro) or 0.625 mg/5 mg (Premphase) orally once daily.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Conjugated estrogens: 10-24 hours (terminal, prolonged in hepatic impairment). Medroxyprogesterone acetate: 12-17 hours (terminal).
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Renal (90-95% as glucuronide and sulfate conjugates; <5% unchanged), biliary/fecal (5-10%).
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category C
Category C
Estrogen/Progestin Combination
Estrogen